GlobeNewswire

Roche’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints

Share

      ·Phase III IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone compared to current standard-of-care (abiraterone and prednisone/prednisolone alone) plus placebo met its co-primary endpoint of radiographic progression free survival (rPFS) in patients with PTEN loss tumours


Basel, 19 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC) and whose tumours had PTEN loss. In this patient group, ipatasertib in combination with abiraterone and prednisone/prednisolone provided a statistically significant reduction in the risk of disease worsening or death, compared to current standard of care (abiraterone and prednisone/prednisolone) plus placebo. The other co-primary endpoint of rPFS in the overall study population (ITT) was not met. The safety profile for the combination of ipatasertib and abiraterone was consistent with previous analyses and known risks. The results of the IPATential150 study will be presented at an upcoming medical meeting.

While initial data are encouraging, overall survival benefit and additional secondary endpoints are not yet mature. The trial will continue until the next planned analysis and data will be shared with health authorities.

“Prostate cancer remains a leading cause of death in men worldwide and patients with metastatic castration-resistant prostate cancer can be difficult to treat,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “The early results of the IPATential150 study are encouraging in our ongoing mission to develop new treatment options for people with advanced prostate cancer.”

Ipatasertib is an oral, highly specific, investigational medicine designed to target and bind to all three isoforms of AKT (protein kinase B), which blocks the PI3K/AKT signalling pathway – a key driver of cancer cell growth and proliferation in prostate cancer.1,2 The PI3K/AKT pathway has also been implicated in resistance to anti-androgen therapy as androgen receptor (AR) inhibition is associated with an increase in AKT pathway activation.2,3 Functional loss of the tumour suppressor protein PTEN within the tumour, seen in approximately 40-60% of mCRPC patients, results in hyperactivation of the PI3K/AKT pathway and is associated with adverse outcomes such as increased tumour grade and stage, earlier biochemical recurrence after radical prostatectomy, metastasis, prostate-cancer-specific death, and androgen-independent progression.4,5

Roche’s clinical development programme for ipatasertib focuses on tumours that are frequently found to have activation of the PI3K/AKT pathway. In addition to prostate cancer, ipatasertib is being studied in certain types of breast cancer including triple-negative breast cancer (TNBC) and hormone-receptor positive (HR+), HER2- negative breast cancer. Results are anticipated later in 2020.

About the IPATential150 study6
IPATential150 is a double-blind, placebo-controlled, randomised phase III study assessing ipatasertib in combination with abiraterone and prednisone/prednisolone, compared to placebo plus abiraterone and prednisone/prednisolone, in adult male patients with asymptomatic or mildly symptomatic, previously untreated mCRPC.

The co-primary endpoints of the study are investigator-determined rPFS in the overall study population, as well as a subpopulation whose tumours have PTEN loss, as assessed by immunohistochemistry (Ventana assay). PFS in the study is defined as the time from date of randomisation to the first occurrence of disease progression or death from any cause, whichever occurs earlier. Secondary endpoints include overall survival, safety, time to pain progression, time to initiation of cytotoxic chemotherapy and time to function deterioration.

About ipatasertib
Ipatasertib is an oral, highly specific, investigational medicine designed to target and bind to all three isoforms of AKT, which blocks the PI3K/AKT signalling pathway and may prevent cancer cell growth and survival.1,2

Ipatasertib is being studied in tumours that are frequently found to have activation of the PI3K/AKT pathway, including breast and prostate cancers. Clinical studies are ongoing to evaluate the efficacy and safety of ipatasertib and the opportunity it may provide to address significant unmet needs for patients with these diseases.

Ipatasertib was discovered at Genentech in partnership with Array BioPharma Inc. (acquired by Pfizer Inc. on July 30, 2019).

About metastatic castration-resistant prostate cancer (mCRPC)
Prostate cancer is the second most frequent cancer and the fifth leading cause of death in men.7 Metastatic prostate cancer refers to prostate cancer that has spread beyond the prostate to other parts of the body (metastasised).8 Although most men are cured with treatment of localised disease, recurrent or newly diagnosed metastatic disease is associated with significant morbidity and mortality.9,10,11

Primary treatment of advanced prostate cancer is androgen deprivation therapy (ADT); however, up to one-third of patients will progress despite reduction in serum testosterone levels to castrate levels (<50 ng/dL), either through surgical or medical castration.12,13 Castration-resistant prostate cancer (CRPC) is defined by disease progression, as measured by prostate specific antigen (PSA) or radiographic measures, despite adequate suppression of serum testosterone levels.14,15 Despite the current availability of life-extending therapies for mCRPC, the majority of men will die of their disease: the median life expectancy in this population is less than three years.16,17

Prostate cancer growth and survival is driven by abnormal AR signalling. In CRPC, cell growth and proliferation is also commonly driven by activation of the PI3K/AKT signalling pathway.1,2 In particular, functional loss of the tumour suppressor protein PTEN within the tumour, seen in approximately 40-60% of people with mCRPC, results in hyperactivation of the PI3K/AKT pathway.4 PTEN loss is associated with adverse outcomes such as increased tumour grade and stage, earlier biochemical recurrence after radical prostatectomy, metastasis, prostate-cancer-specific death, and androgen-independent progression.5 The PI3K/AKT pathway has also been implicated in resistance to anti-androgen therapy as AR inhibition is associated with an increase in AKT pathway activation, suggesting that the tumour compensates for the loss of one pathway with another.2,3

About Roche in prostate cancer
For more than 50 years, Roche has been developing medicines with the goal of redefining treatment in oncology. Our research and development aim is to provide effective cancer therapies through the discovery and development of novel therapeutics that target the specific molecular pathways associated with cancer. Roche is expanding into additional areas of unmet need, working to find innovative solutions for diseases such as prostate cancer, the most prevalent cancer in men and fifth leading cause of cancer-related male death worldwide.5 Roche is committed to research into genitourinary cancers, including bladder and renal cancers, and to providing life extending treatment options for these patients.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Yang J, et al. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019; 18(1).
[2] Crumbaker M, et al. AR Signaling and the PI3K pathway in prostate cancer. Cancers (Basel). 2017; 9(4):34.
[3] Wang Y, et al. Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/AKT pathway in prostate cancer. Current Cancer Drug Targets. 2007; 7(6), 591-604.
[4] De Bono JS, et al. Randomized phase ii study evaluating AKT blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss. Clin Cancer Res. 2019; 25(3);928-36.
[5] Jamaspishvili T, et al. Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol. 2018; 15(4):222-34.
[6] Clinical trials.gov. Ipatasertib plus abiraterone plus prednisone/prednisolone, relative to placebo plus abiraterone plus prednisone/prednisolone in adult male patients with metastatic castrate-resistant prostate cancer (IPATential150). [Internet; cited June 2020]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT03072238?term=ipatential150&draw=2&rank=1
[7] Bray F, et al. Global cancer statistics 2018: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018; 68:394-424.
[8] Cancer.net. Treatment of metastatic castration-resistant prostate cancer. [Internet; cited June 2020]. Available from: www.cancer.net/research-and-advocacy/asco-care-and-treatment-recommendations-patients/treatment-metastatic-castration-resistant-prostate-cancer.
[9] Johansson JE, et al. Natural History of Early, Localized Prostate Cancer. JAMA. 2004;291(22):2713-2719.
[10] Lee R, et al. Treatment and prevention of bone complications from prostate cancer. Bone. 2011; 48 (1): 88-95.
[11] Soest R et al. The Natural History and Outcome Predictors of Metastatic Castration-resistant Prostate Cancer. European Urology Focus. 2016; 2 (5): 480-487.
[12] Petrovich Z, et al. Adenocarcinoma of the prostate: innovations in management. Am J Clin Oncol. 1997;20:111-9.
[13] Petrylak DP. Current state of castration-resistant prostate cancer. Am J Manag Care. 2013;19(18 Suppl):s358‐s365.
[14] Kirby M, et al. Characterising the castration-resistant prostate cancer population: a systematic review. International Journal of Clinical Practice, 2011;65(11);1180–92.
[15] Scher HI, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016; 34(12):1402–1418.
[16] Ryan CJ, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy N. Engl. J. Med. 2013; 368(368):138–148. doi: 10.1056/NEJMoa1209096.
[17] Beer TM, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 2014; 371:424–433. doi: 10.1056/NEJMoa1405095.

Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
- Nicolas Dunant (Head)
- Patrick Barth
- Daniel Grotzky
- Karsten Kleine
- Nathalie Meetz
- Barbara von Schnurbein

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Result of Riksbank´s purchases of Commercial Paper8.7.2020 10:00:00 CESTPress release

Auction date200708 Requested volume, SEK mln4,000 Credit rating class1Term3MRequested volume, SEK mln1,000Fixed purchase rate0.45 %Total bid amount, SEK mln0,000Prel. accepted volume, SEK mln0,000Percentage alloted0.00 %Number of bids0 Credit rating class1Term6MRequested volume, SEK mln1,000Fixed purchase rate0.55 %Total bid amount, SEK mln0,000Prel. accepted volume, SEK mln0,000Percentage alloted0.00 %Number of bids0 Credit rating class2Term3MRequested volume, SEK mln1,000Fixed purchase rate0.75 %Total bid amount, SEK mln75Prel. accepted volume, SEK mln75Percentage alloted100.00 %Number of bids1 Credit rating class2Term6MRequested volume, SEK mln1,000Fixed purchase rate0.85 %Total bid amount, SEK mln40Prel. accepted volume, SEK mln40Percentage alloted100.00 %Number of bids1

Software delivery to Burger King Russian Quick service restaurants8.7.2020 09:00:00 CESTPress release

Malmö - ZetaDisplay AB (publ) (Nasdaq Stockholm: ZETA) announces that its software solution will be part of the Digital Signage installation for more than 750 Burger RUS quick service restaurants (QSR) in the Russian Federation countries. ZetaDisplay’s Norwegian subsidiary Webpro has signed a deal with the domestic integrator company Unitex LLC that will deliver the project. The contract is valid initially for one year and can be extended for four further years thereafter. The total contract value for ZetaDisplay is estimated at 3.3 MSEK consisting entirely of SaaS-revenues. “This agreement is another proof for our ability of being able to handle complex international assignments. Congratulations to the Norwegian team for this achievement”, comments Per Mandorf, President and CEO of ZetaDisplay. “Our solution was considered best in test during the evaluation phase and we are proud of the trust that the customer puts into our capabilities”. ZetaDisplay is the leading provider of Digital

Mjukvaruleverans till Burger Kings ryska snabbmatsrestauranger8.7.2020 09:00:00 CESTPressemelding

Malmö - ZetaDisplay AB (publ) (Nasdaq Stockholm: ZETA) meddelar att dess mjukvara kommer att vara en del av Digital Signage installation för mer än 750 Burger RUS snabbmatsrestauranger i ryska federationen och OSS-länder. ZetaDisplays norska dotterbolag Webpro har tecknat avtal med det inhemska installationsföretag Unitex LLC. Kontraktet sträcker sig initialt på ett år, och kan därefter förlängas ytterligare fyra år. Det totala kontraktsvärdet för ZetaDisplay uppskattas till 3,3 MSEK som består helt av SaaS-intäkter. – Det här avtalet är ytterligare ett bevis på vår förmåga att kunna hantera ett komplext internationellt uppdrag. Grattis till det norska teamet för denna framgång", kommenterar Per Mandorf, VD och koncernchef för ZetaDisplay. "Vår lösning ansågs vara bäst i test under utvärderingsfasen och vi är stolta över det förtroende som kunden sätter i vår kompetens". ZetaDisplay är den ledande leverantören av Digital Signage-lösningar för snabbmatsrestauranger (QSR) i den ryska fed

Eolus Vind AB delårsrapport 1 mars 2020 – 31 maj 20208.7.2020 08:30:00 CESTPressemelding

Hässleholm den 8 juli 2020 Verksamhetsårets tredje period 1 mars 2020 – 31 maj 2020 Nettoomsättningen uppgick till 380,6 (520,3) MSEK.Rörelseresultatet uppgick till 38,1 (10,9) MSEK. Resultat före skatt uppgick till 13,5 (10,0) MSEK. Periodens resultat efter skatt uppgick till 17,6 (12,2) MSEK.Resultat per aktie före och efter utspädning uppgick till 0,71 (0,49) SEK.Under perioden togs 0 (0) nya vindkraftverk med en total effekt om 0 (0) MW i drift.Under perioden överlämnades motsvarande 0 (1) vindkraftverk med en total effekt om 0,0 (2,0) MW till kund.Vid periodens utgång omfattade koncernens förvaltningsverksamhet 687 (421) MW.Projektbolaget Øyfjellet Wind AS, som Eolus är byggnationsansvarig för, tecknade i mars 2020 turbinleveransavtal med Nordex omfattande 72 vindkraftverk av modell N149 med en total installerad effekt om 400 MW. Ett 20-årigt Premium servicekontrakt med option på förlängning tecknades samtidigt. Väsentliga händelser efter rapportperiodens utgång I juli tecknade Eo

Eolus Vind AB interim report March 1 2020 – May 31 20208.7.2020 08:30:00 CESTPress release

Hässleholm, Sweden, July 8, 2020 3 Months March 2020 – May 2020 Net sales 380.6 (520.3) MSEK.EBIT 38.1 (10.9) MSEK. Profit before tax 13.5 (10.0) MSEK. Net profit 17.6 (12.2) MSEK.Earnings per share, before and after dilution equals 0.71 (0.49) SEK.During the three month period 0 (0) wind turbines were taken into operations with a total installed capacity of 0 (0) MW.During the three month period the equivalent of 0 (1) wind turbines with an installed capacity of 0 (2.0) MW was handed over to customers.At the end of the period Eolus had 687 (421) MW under asset management.In March 2020 the project company Øyfjellet Wind AS, which Eolus has a construction management agreement with, signed a turbine supply agreement with Nordex regarding 72 wind turbines of the model N149 with a total installed capacity of 400 MW. A 20-year Premium Service contract with options for extension was also signed. Significant events after the balance sheet date In July Eolus signed a cooperation agreement with

Auriant Mining AB (publ.) publicerar verksamhetsuppdatering för H1 20208.7.2020 08:20:00 CESTPressemelding

Viktiga händelser: Den totala guldproduktionen under H1 2020 uppgick till 521 kg (16 750 oz), jämfört med 255 kg (8 189 oz) under H1 2019, en ökning med 105% eller 266 kg (8 561 oz). Malmbaserad guldproduktion vid Tardan ökade från 227 kg (7 308 oz) under H1 2019 till 521 kg (16 750 oz) under H1 2020 eller med 129%;Guldförsäljning under H1 2020 uppgick till 537 kg (17 249 oz), jämfört med 238 kg (7 640 oz) under H1 2019, en ökning med 299 kg (9 609 oz) eller 125%;Volymen av malm som bearbetats genom den nybyggda CIL-anläggningen uppgick till 196 kt med en snitthalt om 2,87 g/t (guld i malmen totalt - 561 kg);CIL-anläggningen var i drift med beräknad bearbetningskapacitet per arbetstimme (>50 ton/timme) och återvinningsgrad (92.9%);Lakning på hög avbröts i slutet av december 2019;Volymen för den brutna malmen uppgick till 151 kt (20% lägre än under samma period föregående år). Arbetsvolymen för avrymningen uppgick till 429 km3 under H1 2020 (17% lägre än under H1 2019);Snitthalten i mal